QuidelOrtho Corp (QDEL)

27.54 -0.88 (-3.09%)

As of 2025-10-16 15:16:27 EST

QuidelOrtho Corporation is an American manufacturer of diagnostic healthcare products that are sold worldwide. On May 8, 2020 the U.S. Food and Drug Administration (FDA) issued to Quidel the first emergency use authorization (EUA) for a COVID-19 rapid antigen test, a new category of tests for use in the ongoing pandemic. These diagnostic tests quickly detect fragments of proteins found on or within the virus by testing samples collected from the nasal cavity using swabs.

Traded asNasdaq: QDEL
ISINUS2197981051
CIK0001906324
LEI549300YU8CMO9HF53113
EIN874496285
Sector—
IndustryIn Vitro & In Vivo Diagnostic Substances
CEOBrian Blaser
Employees7,100
Fiscal Year End0101
Address9975 SUMMERS RIDGE ROAD, SAN DIEGO, CA, 92121
Phone(858) 552-1100
Websitehttp://quidelortho.com
Stock Quotes
trading_symbolregistrant_nametimepricechangepercentage_change
QDELQuidelOrtho Corp2025-10-16 15:16:2727.54-0.88-3.09
This is a preview of the latest data. Subscribe to access the full data.
Company Information
trading_symbolcentral_index_keyregistrant_nameisin_numberlei_numberein_numberexchangesic_codesic_descriptionfiscal_year_endstate_of_incorporationaddress_streetaddress_cityaddress_stateaddress_zip_codeaddress_countryaddress_country_codephone_numbermailing_addressbusiness_addressformer_nameindustryfounding_datechief_executive_officernumber_of_employeeswebsitemarket_capshares_issuedshares_outstandingdescriptionupdate_time
QDEL0001906324QuidelOrtho CorpUS2197981051549300YU8CMO9HF53113874496285Nasdaq2835In Vitro & In Vivo Diagnostic Substances0101—9975 SUMMERS RIDGE ROADSAN DIEGOCA92121UNITED STATESUS(858) 552-11009975 SUMMERS RIDGE ROAD, SAN DIEGO, CA, 921219975 SUMMERS RIDGE ROAD, SAN DIEGO, CA, 92121Coronado Topco, Inc.—1979Brian Blaser7,100http://quidelortho.com2,182,619,27767,700,00067,900,466QuidelOrtho Corporation is an American manufacturer of diagnostic healthcare products that are sold worldwide. On May 8, 2020 the U.S. Food and Drug Administration (FDA) issued to Quidel the first emergency use authorization (EUA) for a COVID-19 rapid antigen test, a new category of tests for use in the ongoing pandemic. These diagnostic tests quickly detect fragments of proteins found on or within the virus by testing samples collected from the nasal cavity using swabs.2025-10-10 20:46:02
This is a preview of the latest data. Subscribe to access the full data.
QDEL Stock Price (End-of-Day)
This is a preview of the latest data. Subscribe to access the full data.
QDEL Stock Price (1-Minute)
This is a preview of the latest data. Subscribe to access the full data.
Market Cap
Fiscal YearMarket CapChange In Market CapPercentage Change In Market CapShares OutstandingChange In Shares OutstandingPercentage Change In Shares Outstanding
20242,182,619,277-2,906,952,565-57.115967,446,544597,0540.8931
20235,089,571,842-918,630,753-15.289666,849,490343,9440.5172
20226,008,202,5956,008,202,59510066,505,54666,505,546100
This is a preview of the latest data. Subscribe to access the full data.
Executive Compensation
Executive NameExecutive PositionFiscal YearSalaryBonusStock AwardsIncentive Plan CompensationOther CompensationTotal Compensation
Robert J. BujarskiEVP, President, COO2024575,76302,999,91702,862,7976,438,477
Michael S. IskraCEO, EVP2024575,76302,999,91702,615,8936,191,573
Brian J. BlaserCEO, President2024634,615013,434,938863,014112,37015,044,937
Douglas C. BryantCEO, President2024176,67706,199,87934,6135,638,89612,050,065
Patrick E. KleinSVP2024136,7500642,92301,407,1112,543,141
This is a preview of the latest data. Subscribe to access the full data.
Employee Count
Fiscal YearEmployee Count
20246,600
20237,000
This is a preview of the latest data. Subscribe to access the full data.
Income Statements
Fiscal Year202420232022
Revenue2,782,900,0002,997,800,0003,266,000,000
Cost Of Revenue1,496,400,0001,503,400,0001,330,000,000
Gross Profit29,500,000—18,600,000
Research And Development Expenses218,700,000246,800,000190,500,000
General And Administrative Expenses766,800,000763,200,000621,000,000
Operating Expenses125,400,000124,100,000104,900,000
Operating Income-1,960,900,000139,100,000843,700,000
Net Income-2,052,000,000-10,100,000548,700,000
Earnings Per Share Basic-30.54-0.159.66
Earnings Per Share Diluted-30.54-0.159.56
Weighted Average Shares Outstanding Basic67,200,00066,800,00056,800,000
Weighted Average Shares Outstanding Diluted67,200,00066,800,00057,400,000
This is a preview of the latest data. Subscribe to access the full data.
Balance Sheet Statements
Fiscal Year202420232022
Cash And Cash Equivalents98,300,000118,900,000292,900,000
Marketable Securities Current048,400,00052,100,000
Accounts Receivable282,400,000303,300,000453,900,000
Inventories533,700,000577,800,000524,100,000
Non Trade Receivables—104,700,00038,600,000
Other Assets Current1,100,0003,100,000900,000
Total Assets Current1,218,900,0001,310,500,0001,575,100,000
Marketable Securities Non Current07,400,00021,000,000
Property Plant And Equipment—1,443,800,0001,339,000,000
Other Assets Non Current270,700,000179,600,000122,700,000
Total Assets Non Current5,204,700,0001,443,800,0001,339,000,000
Total Assets6,423,600,0008,563,100,0008,855,800,000
Accounts Payable246,000,000294,800,000283,300,000
Deferred Revenue33,500,00036,800,00076,400,000
Short Term Debt341,800,000139,800,000207,500,000
Other Liabilities Current288,700,000303,300,000325,400,000
Total Liabilities Current998,800,000833,800,0001,007,000,000
Long Term Debt2,488,600,0002,422,600,0002,648,900,000
Other Liabilities Non Current55,300,00083,600,00083,800,000
Total Liabilities Non Current2,440,300,0002,723,400,0002,914,200,000
Total Liabilities3,439,100,0003,557,200,0003,921,200,000
Common Stock100,000100,0000
Retained Earnings135,800,0002,187,800,0002,197,900,000
Accumulated Other Comprehensive Income-36,200,000-30,000,000-67,600,000
Total Shareholders Equity2,984,500,0005,005,900,0004,934,600,000
This is a preview of the latest data. Subscribe to access the full data.
Cash Flow Statements
Fiscal Year202420232022
Depreciation And Amortization250,000,000252,400,000151,100,000
Share Based Compensation Expense42,100,00051,600,00048,400,000
Other Non Cash Income Expense-1,200,000——
Change In Accounts Receivable-5,400,000-160,000,000-150,200,000
Change In Inventories134,100,000211,600,000116,900,000
Change In Non Trade Receivables———
Change In Other Assets———
Change In Accounts Payable-23,400,0003,000,00023,500,000
Change In Other Liabilities-22,600,000-5,900,000-75,200,000
Cash From Operating Activities83,000,000280,200,000885,300,000
Purchases Of Marketable Securities7,200,00060,100,00063,700,000
Sales Of Marketable Securities63,100,00078,300,00053,400,000
Acquisition Of Property Plant And Equipment195,100,000209,300,000140,900,000
Acquisition Of Business001,511,400,000
Other Investing Activities20,000,00010,000,000—
Cash From Investing Activities-149,900,000-187,600,000-1,644,200,000
Tax Withholding For Share Based Compensation9,600,00013,500,0008,600,000
Payments Of Dividends———
Issuance Of Common Stock5,000,00011,600,00026,400,000
Repurchase Of Common Stock07,200,00074,300,000
Issuance Of Long Term Debt———
Repayment Of Long Term Debt———
Other Financing Activities———
Cash From Financing Activities48,800,000-265,800,000252,000,000
Change In Cash-21,000,000-174,400,000-508,900,000
Cash At End Of Period98,300,000118,900,000292,900,000
Income Taxes Paid41,600,00086,600,000264,800,000
Interest Paid177,500,000150,000,00095,100,000
This is a preview of the latest data. Subscribe to access the full data.
Key Metrics
Fiscal Year20242023
Earnings Per Share-30.54-0.15
Price To Earnings Ratio-1.4407-491.3333
Earnings Growth Rate20,260-101.5528
Price Earnings To Growth Ratio-0.00014.8382
Book Value Per Share44.412274.9386
Price To Book Ratio0.99070.9835
Ebitda-1,923,900,000181,300,000
Enterprise Value5,688,900,0007,366,660,000
Dividend Yield——
Dividend Payout Ratio——
Debt To Equity Ratio0.94840.5119
Capital Expenditures—357,200,000
Free Cash Flow—-77,000,000
Return On Equity-0.6876-0.002
One Year Beta0.52861.0431
Three Year Beta0.9070.737
Five Year Beta0.58110.6458
This is a preview of the latest data. Subscribe to access the full data.
Insider Transactions
Insider NameRelationship To IssuerTransaction DateAmount Of SecuritiesAcquired Or DisposedSecurities Owned Following Transaction
Bowman Ronald LeeChief Human Resources Officer2025-09-152,565A2,565
Bowman Ronald LeeChief Human Resources Officer2025-09-15918D1,647
Bowman Ronald LeeChief Human Resources Officer2025-09-152,565D5,132
BUECHLER KENNETH FDirector2025-07-159,215A101,921
BUECHLER KENNETH FDirector2025-07-159,215D0
This is a preview of the latest data. Subscribe to access the full data.
House Trading
Name Of Reporting PersonReport DateStateTransaction TypeTransaction DateOwner TypeAmount
Daniel Goldman2023-08-13NY10Sale2023-07-12—$1,001 - $15,000
This is a preview of the latest data. Subscribe to access the full data.
Institutional Holdings
Investor NamePeriod Of ReportMarket ValueAmount Of SecuritiesPrice Per Security
RICE HALL JAMES & ASSOCIATES, LLC2025-09-307,625,017258,91429.45
Blue Trust, Inc.2025-09-30147529.4
CWM, LLC2025-09-30199,0006,76529.4161
First PREMIER Bank2025-09-306,00020030
Stephens Consulting, LLC2025-09-301,5615329.4528
This is a preview of the latest data. Subscribe to access the full data.
Mutual Fund Holdings
Registrant NamePeriod Of ReportFund NameFund SymbolAmount Of UnitsValue In UsdPercentage Value Compared To Assets
TRUST FOR PROFESSIONAL MANAGERS2025-08-31Column Small Cap FundCFSLX9,522273,186.180.057
TRUST FOR PROFESSIONAL MANAGERS2025-08-31Column Small Cap Select FundCFSSX19,839569,180.910.0396
RUSSELL INVESTMENT CO2025-07-31Class YRUSPX-16,072-369,977.44-0.0113
RUSSELL INVESTMENT CO2025-07-31Class MRUSTX-16,072-369,977.44-0.0113
RUSSELL INVESTMENT CO2025-07-31Class SRSESX-16,072-369,977.44-0.0113
This is a preview of the latest data. Subscribe to access the full data.